[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@RAH00084 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1450478271179759623.png) @RAH00084 RAH

RAH posts on X about $abve, novartis, accounting, $3bn the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1450478271179759623/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1450478271179759623/c:line/m:interactions.svg)

- X Week XXXXXX +40%
- X Month XXXXXX +216%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +5.70%

### Mentions: XX [#](/creator/twitter::1450478271179759623/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1450478271179759623/c:line/m:posts_active.svg)

- X Week XX +72%
- X Month XX +159%
- X Months XXX -XX%
- X Year XXX +51%

### Followers: XXXXX [#](/creator/twitter::1450478271179759623/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1450478271179759623/c:line/m:followers.svg)

- X Week XXXXX +0.08%
- X Month XXXXX +1.50%
- X Months XXXXX +5.40%
- X Year XXXXX +1%

### CreatorRank: XXXXXXX [#](/creator/twitter::1450478271179759623/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1450478271179759623/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1450478271179759623/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXXX% [finance](/list/finance)  XXXX%

**Social topic influence**
[$abve](/topic/$abve) #7, [novartis](/topic/novartis) #3, [accounting](/topic/accounting) 2.86%, [$3bn](/topic/$3bn) 2.86%, [market cap](/topic/market-cap) 2.86%, [$abbv](/topic/$abbv) 2.86%, [$21bn](/topic/$21bn) 2.86%, [next to](/topic/next-to) 2.86%, [targets](/topic/targets) 2.86%, [integration](/topic/integration) XXXX%

**Top accounts mentioned or mentioned by**
[@neilsbhatia](/creator/undefined) [@peterknez](/creator/undefined) [@spcowins](/creator/undefined) [@ragebait500](/creator/undefined) [@grok](/creator/undefined) [@tom_the_bomb__](/creator/undefined) [@stepnotonpets](/creator/undefined) [@justinss55](/creator/undefined) [@asininitybeyond](/creator/undefined) [@henriknielsen9g](/creator/undefined) [@regsnowdon](/creator/undefined) [@avacta](/creator/undefined) [@yieldcurvebali](/creator/undefined) [@procrasprognos](/creator/undefined) [@tomthebomb](/creator/undefined) [@blueberrymgmnt](/creator/undefined) [@cbz](/creator/undefined) [@tempusai](/creator/undefined) [@blackrock](/creator/undefined) [@oldunclestock](/creator/undefined)

**Top assets mentioned**
[Novartis AG (NVS)](/topic/novartis) [AbbVie Inc (ABBV)](/topic/$abbv)
### Top Social Posts [#](/creator/twitter::1450478271179759623/posts)
---
Top posts by engagements in the last XX hours

"@neilsbhatia $ABVE audit is being undertaken by @cbz. XX years experience. XX offices. XXX shareholders. 7th largest accounting firm in . Listed ($3Bn market cap) and regulated. Employed by ABVE specifically because of their tokenisation experience. Audit completion = 💥"  
[X Link](https://x.com/RAH00084/status/1977672747905098041) [@RAH00084](/creator/x/RAH00084) 2025-10-13T09:48Z 2527 followers, 3288 engagements


"Follow the warrants $ABVE"  
[X Link](https://x.com/RAH00084/status/1977802456521425354) [@RAH00084](/creator/x/RAH00084) 2025-10-13T18:23Z 2527 followers, 2841 engagements


"Its so clear Novartis are sizing up #AVCTs AVA6207"  
[X Link](https://x.com/RAH00084/status/1980940415365792164) [@RAH00084](/creator/x/RAH00084) 2025-10-22T10:12Z 2527 followers, 6769 engagements


"Pharmacyclics was acquired by AbbVie for $21Bn in 2015. Sales of Imbruvica are now taking a hit from BeiGenes drug Brukinsa. It happens. Its pharma. Pharmacyclics did x200 from its low for these projected sales. #AVCT can too. Its not the stretch it appears if you understand preCISION. Heres just one (actually quite conservative) route: ➡ AVA6000 replaces the benchmark (which is currently a cocktail of drugs) in salivary gland cancer (SGC) and runs 400m sales pa in 3/4 years (assume pharma pay x4 for those sales in said indication) 1.6Bn. Beating the benchmark now very likely according to the"  
[X Link](https://x.com/RAH00084/status/1926524708331180087) [@RAH00084](/creator/x/RAH00084) 2025-05-25T06:24Z 2526 followers, 23K engagements


"Isnt this exactly the type of appointment which suggests it is indeed happening. Note the date of appointment. @neilsbhatia $ABVE"  
[X Link](https://x.com/RAH00084/status/1976261140368773175) [@RAH00084](/creator/x/RAH00084) 2025-10-09T12:19Z 2526 followers, 5429 engagements


"@tom_the_bomb__ @asininitybeyond @Blueberrymgmnt Stick a couple of JVs next to those assets and it looks like a 5Bn+ company to me. #AVCT"  
[X Link](https://x.com/RAH00084/status/1980287221509865619) [@RAH00084](/creator/x/RAH00084) 2025-10-20T14:57Z 2526 followers, 1982 engagements


"@tom_the_bomb__ @grok Novel surface targets 👀 Perhaps #AVCT went for the Novartis colour scheme on rebrand to save on integration costs.😉"  
[X Link](https://x.com/RAH00084/status/1980961501222404388) [@RAH00084](/creator/x/RAH00084) 2025-10-22T11:36Z 2527 followers, 1825 engagements


"Months not years $ABVE"  
[X Link](https://x.com/RAH00084/status/1977325285281562811) [@RAH00084](/creator/x/RAH00084) 2025-10-12T10:47Z 2524 followers, 10.5K engagements


"#AVCT has finally learnt to play license deal chess. The difference between former and current management is a lot like doxorubicin vs AVA6000: chalk & cheese. Bolstering your balance sheet during pivotal discussions is strategy XXX. This is not AS part . Now watch it run"  
[X Link](https://x.com/RAH00084/status/1980156634753307037) [@RAH00084](/creator/x/RAH00084) 2025-10-20T06:18Z 2525 followers, 5970 engagements


"#AVCT X Dec 2022 - Prometheus released results of two P2 (12-week) studies. Off the back of this data they raised $500m (Dec 2022). X months later (Apr 2023) they were bought out for $10.8Bn ($193 per share). Negotiation from a position of strength. Basic stuff"  
[X Link](https://x.com/RAH00084/status/1980182316137013493) [@RAH00084](/creator/x/RAH00084) 2025-10-20T08:00Z 2525 followers, 2899 engagements


"@grok Blind as a bat @grok But thats ok youll improve"  
[X Link](https://x.com/RAH00084/status/1980948576336228700) [@RAH00084](/creator/x/RAH00084) 2025-10-22T10:45Z 2525 followers, XXX engagements


"And the company as a whole"  
[X Link](https://x.com/RAH00084/status/1980940620005773663) [@RAH00084](/creator/x/RAH00084) 2025-10-22T10:13Z 2527 followers, 1032 engagements


"#AVCT Novartis interest in FAP via @grok"  
[X Link](https://x.com/RAH00084/status/1980948206142787651) [@RAH00084](/creator/x/RAH00084) 2025-10-22T10:43Z 2527 followers, 2641 engagements


"There is not a rational commentator who would place #AVCTs chance of success in SGC south of XX% right now. As you say it is beating the benchmark in a heavily pre treated population of patients. If you assume 200m sales and a x5 multiple (conservative on both accounts) you land on 1Bn. Assume 500m in issue (funded to takeover). Thats 200p per share. XX% CoS in SGC only = 100p XXX% CoS in SGC only = 200p And so forth To be sat at 63p today implies: AVA6000 in SGC - XX% CoS (it is doubling the benchmark PFS) AVA6000 in TNBC - X% CoS (we have been told P1b data has increased their confidence in"  
[X Link](https://x.com/RAH00084/status/1981348549246808517) [@RAH00084](/creator/x/RAH00084) 2025-10-23T13:14Z 2527 followers, 2263 engagements